Actively Recruiting
Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
Led by Xijing Hospital · Updated on 2025-02-07
30000
Participants Needed
1
Research Sites
1326 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.
CONDITIONS
Official Title
Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- available for 5 years of follow-up study
You will not qualify if you...
- Death caused other than cardiovascular and cerebralvascular diseases till the study ends
- Floating Population
- Pregnancy, lactation, or child bearing women
- Tumor
- Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL
- Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L)
- Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xijing Hospital
Xi'an, Shaanxi, China, 710032
Actively Recruiting
Research Team
L
Ling Tao, M.D Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here